|Last Price$47.60||Day Change (%)1.45%|
|Open Price$47.14||Day Change ($)0.68|
|Day Range47.01–47.77||52-Week Range32.18–49.48|
As of Fri 9/30/2016 7:08:00 PM | USD
Artificial Organs - Global Strategic Business Report 2016-2022: 3D Printing Revolutionizing the Medical Industry's Artificial Organ Development Segment - Research and Markets
Fitch Rates Lake County, Illinois' Water and Sewer Revs 'AAA'; Outlook Stable
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
David Watson to Join SSI Group as Executive Vice President
OvaScience Announces Executive Management Changes and Appointments to Further Drive Company’s Growth
Although 2015 may be rocky, both Baxter and Baxalta should see significant margin expansion and growth in the long term, says Morningstar's Karen Andersen.
Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.